Proteins, as the primary executors of biological functions, serve as a core focus in biopharmaceutical research and a critical tool for advancing innovative therapies. As drug targets, they enable researchers to identify and validate key disease-related molecules, facilitating the development of highly specific therapeutics that minimize harm to healthy tissues. In drug screening and optimization, high-throughput screening and structural biology techniques help assess drug-target binding affinity, improving efficacy and safety. Through genetic and protein engineering, scientists can modify and optimize biologics to enhance stability, prolong half-life, increase potency, or reduce immunogenicity. Consequently, proteins are now widely applied in disease treatment, targeted therapy, immune regulation, and diagnostics. However, challenges remain in their development, including expression and purification, stability, immunogenicity, and manufacturing processes.
ACROBiosystems’ protein development platform is designed around protein structure and application requirements, providing high-quality protein products and technical support to the global biopharmaceutical industry to accelerate drug development and commercialization. The platform integrates protein design and optimization, high-efficiency expression systems, high-throughput screening and analysis, and process development and optimization. By leveraging these advanced technologies, ACROBiosystems aims to drive the discovery of transformative therapies and contribute to improving human health.
ACROBiosystems adheres to the principle of "Quality by Design (QbD)", ensuring high-quality and functional proteins from the very beginning. In recent years, AI has demonstrated remarkable potential in revolutionizing various industries, and the life sciences and medical innovation fields are no exception. Within this landscape, AI-driven protein design and engineering has emerged as a rapidly advancing frontier. Establishing an AI- driven protein engineering platform holds immense promise for enhancing the quality and yield of recombinant proteins, improving R&D efficiency, reducing costs, and accelerating biopharmaceutical innovation.
ACROBiosystems has developed its own AI Protein Dry-Wet Closed-Loop System.
• For protein expression prediction, leveraging over a decade of proprietary data and expertise in mammalian cell protein expression, we have trained DeepExp, a highly accurate model (AUC=0.95) that predicts the secretory expression levels of recombinant proteins in mammalian cells. Unlike traditional methods limited to signal peptide prediction, DeepExp overcomes the critical challenge of forecasting full-length protein secretion—making it the first known AI model for eukaryotic secretory protein expression prediction.
• For prokaryotic expression systems, we have developed ProDeSol, the most accurate solubility prediction model to date (AUC=0.94), significantly outperforming published alternatives (e.g., GPSfun, AUC=0.65). This breakthrough enables precise solubility optimization for prokaryotic-expressed proteins.
By integrating AI with deep biological insights, ACROBiosystems is redefining protein design — turning challenges into opportunities for next-generation therapeutics.
AI Protein Dry-Wet Closed-Loop System
Regarding protein redesign capabilities, ACROBiosystems has developed the “AI Box” Protein Engineering Toolkit. This platform enables autonomous optimization of multiple key protein properties including binding affinity, stability, salt tolerance, pH resistance, solubility, and enzymatic activity. With a particular focus on addressing critical challenges in cell and gene therapy, the toolkit has successfully developed essential core materials such as
GMP Salt Active GENIUS™Nuclease to overcome key technical bottlenecks in this field.
Protein expression is a critical step in protein development, where the choice of expression system and the inherent difficulty of expression directly impact project success. During drug development, different types of proteins present distinct challenges—from simple recombinant proteins to functionally active proteins requiring complex post-translational modifications, and even structurally intricate transmembrane proteins or multi-subunit protein complexes. Each protein demands a tailored expression strategy to achieve optimal results.
Comprehensive Protein Expression Platform
With years of technological expertise, ACROBiosystems has established a full-spectrum protein expression platform to deliver optimal solutions for proteins with varying characteristics.
For prokaryotic expression, our well-optimized E. coli system offers rapid production and cost-effectiveness, making it ideal for simple recombinant proteins. When post-translational modifications are required, eukaryotic systems such as yeast (providing basic glycosylation with high yield) or insect cells (enabling proper folding for moderately complex proteins) become the preferred choices.
The most challenging proteins — particularly those for biomedical research like therapeutic antigens — benefit from our mammalian cell expression platform, which faithfully replicates human-like protein modifications. Additionally, our cell-free expression system emerges as a groundbreaking alternative for toxic or difficult-to-express proteins, combining ultra-short development cycles with flexible engineering capabilities—perfect for rapid prototyping or non-natural amino acid incorporation.
ACROBiosystems’ technical team collaborates closely with clients to overcome expression hurdles, from basic research to industrial-scale production. By evaluating protein properties, application needs, timelines, and budgets, we design systematic expression strategies and process optimizations. Our innovative hybrid expression approach significantly boosts success rates for "hard-to-express" targets (e.g., multi-pass transmembrane proteins or viral proteins), laying a solid foundation for structural studies, antibody development, and drug screening.
ACROBiosystems has developed an automated, high-throughput protein screening platform that integrates end-to-end solutions—from gene construction and clone screening to cell culture and protein purification. Utilizing standardized high-throughput workflows, the platform enables rapid identification of high-expression, high-stability protein variants from extensive cell libraries.
Innovatively incorporating AI-driven analytics, the platform intelligently analyzes protein structure and function data to pinpoint critical mutation sites, significantly enhancing the success rate of protein engineering. This approach has already demonstrated substantial impact in multiple therapeutic protein development projects, particularly in improving protein expression levels and stability.
High-Throughput Protein Screening Platform
To ensure reliable and reproducible results, ACROBiosystems' platform features a robust high-throughput activity assay system, continuously optimized automated processes, and stringent quality control. This empowers researchers with efficient and precise protein development solutions, accelerating the path from discovery to application.
As critical upstream raw materials for biopharmaceutical R&D, protein products directly determine the accuracy and success of downstream drug development. Serving as the gatekeeper of protein quality, our quality control platform provides essential safeguards for the reliability and functionality of core reagents. Through systematic quality evaluation and control, we deliver scientific foundations for research decisions while ensuring the safety and efficacy of biopharmaceutical products.
ACROBiosystems has established an industry-leading protein quality control platform, implementing a full lifecycle quality control system for therapeutic proteins in compliance with the highest international standards. The platform holds multiple global certifications including ISO 9001:2015, ISO 13485:2016, CNAS, GMP, and DMF filings, demonstrating full alignment with regulatory requirements.
ACROBiosystems Quality System Development Timeline
At the implementation level, we have established a rigorous quality control process that includes:
• Testing over 15 critical parameters (concentration, purity, molecular weight, activity, stability, residuals, endotoxin levels)
• Conducting 30+ tests per batch to ensure data reliability
• Implementing a 4-stage review system (raw materials, in-process, release, documentation)
• Enforcing 3-tier release controls (intermediate, semi-finished, and final products)
This comprehensive QC system ensures consistent, high-quality protein production.
Strict Quality Control Procedures
Our quality control platform integrates a comprehensive suite of advanced analytical technologies including high-performance liquid chromatography (HPLC), size-exclusion chromatography with multi-angle light scattering (SEC-MALS), enzyme-linked immunosorbent assay (ELISA), surface plasmon resonance (SPR), bio-layer interferometry (BLI), fluorescence-activated cell sorting (FACS), and cell-based functional assays. This multi-dimensional analytical system enables complete characterization of protein structure, function, and stability. By employing this integrated technology platform, we ensure batch-to-batch consistency of high-quality protein reagents, with all testing performed under Good Laboratory Practice (GLP) standards accompanied by fully traceable raw data. Our quality control system provides end-to-end support for biopharmaceutical development, from early-stage screening through clinical application, while continuously driving innovation to elevate industry standards for protein reagent quality.
ACROBiosystems' “Structure & Application Integrated” Protein Development Platform combines multiple core technologies, including structure-guided design, multi-omics data analysis, process development and optimization, and customized protein engineering services. These capabilities not only enhance the efficiency and quality of protein development but also provide robust support for biopharmaceutical research and development.
For biopharmaceutical applications, maintaining native conformation, structural homogeneity, and functional activity of antigenic proteins is critical. Leveraging our proprietary technology platforms - including homo/hetero multimer development, nanoparticle antigen display, "Full Length Active Gallery" multi-pass transmembrane protein R&D platform, and “Star Staining” site-specific fluorescent labeling platform - we conduct in-depth investigations into protein structure-function relationships. These specialized platforms enable us to deliver proteins with superior quality and performance characteristics, truly embodying our commitment to "Where Proteins and Innovations Advance Biomedicine."
Featured Technology Platform Display
In terms of successful applications, our platform has been widely utilized across multiple therapeutic areas including antibody drug development, cell and gene therapies, and vaccine research. We have helped clients overcome numerous technical challenges, significantly accelerating the development and commercialization timeline for various biopharmaceutical products.
At ACROBiosystems, we drive protein science innovation to empower global biopharma.
Our advanced platforms deliver high-quality protein solutions that accelerate drug discovery and development.
We invite you to contact us to explore how we can support your research goals and advance therapies for patients worldwide.
Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one. 
A-Z
